Lixte Biotechnology (LIXT) Competitors

Lixte Biotechnology (NASDAQ:LIXT) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, community ranking, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

Do analysts rate LIXT or SNSE?

Sensei Biotherapeutics has a consensus price target of $4.25, indicating a potential upside of 1,372.12%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Sensei Biotherapeutics is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lixte Biotechnology	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sensei Biotherapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more volatility and risk, LIXT or SNSE?

Lixte Biotechnology has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500. Comparatively, Sensei Biotherapeutics has a beta of 0.16, suggesting that its stock price is 84% less volatile than the S&P 500.

Is LIXT or SNSE more profitable?

Sensei Biotherapeutics' return on equity of -53.86% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lixte Biotechnology	N/A	-5,562.77%	-130.48%
Sensei Biotherapeutics	N/A	-53.86%	-46.91%

Does the MarketBeat Community prefer LIXT or SNSE?

Sensei Biotherapeutics received 30 more outperform votes than Lixte Biotechnology when rated by MarketBeat users.

Company	Underperform	Outperform
Lixte Biotechnology	N/A	N/A
Sensei Biotherapeutics	Outperform Votes 30 81.08%	Underperform Votes 7 18.92%

Which has higher earnings and valuation, LIXT or SNSE?

Lixte Biotechnology is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lixte Biotechnology	N/A	N/A	-$5.09M	-$1.59	-0.76
Sensei Biotherapeutics	N/A	N/A	-$34.10M	-$1.20	-0.24

Does the media favor LIXT or SNSE?

In the previous week, Sensei Biotherapeutics had 1 more articles in the media than Lixte Biotechnology. MarketBeat recorded 5 mentions for Sensei Biotherapeutics and 4 mentions for Lixte Biotechnology. Sensei Biotherapeutics' average media sentiment score of 0.23 beat Lixte Biotechnology's score of -0.34 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lixte Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sensei Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders & institutionals have more ownership in LIXT or SNSE?

5.1% of Lixte Biotechnology shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 14.8% of Lixte Biotechnology shares are owned by insiders. Comparatively, 22.0% of Sensei Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Sensei Biotherapeutics beats Lixte Biotechnology on 12 of the 14 factors compared between the two stocks.